Abbott has bolstered its oncology pipeline by signing an exclusive worldwide licensing agreement with Pierre Fabre SA. Abbott will pay US$25 M upfront to develop and commercialize h224G11; a preclinical monoclonal antibody targeting the cMet receptor for the treatment of cancer.